Michelle M Nuño1,2, Joshua D Grill3,4,5, Daniel L Gillen3,6. 1. Children's Oncology Group, Monrovia, CA, USA. 2. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. 3. Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA. 4. Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA, USA. 5. Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, USA. 6. Department of Statistics, University of California, Irvine, Irvine, CA, USA.
Abstract
BACKGROUND/AIMS: The focus of Alzheimer's disease studies has shifted to earlier disease stages, including mild cognitive impairment. Biomarker inclusion criteria are often incorporated into mild cognitive impairment clinical trials to identify individuals with "prodromal Alzheimer's disease" to ensure appropriate drug targets and enrich for participants likely to develop Alzheimer's disease dementia. The use of these eligibility criteria may affect study power. METHODS: We investigated outcome variability and study power in the setting of proof-of-concept prodromal Alzheimer's disease trials that incorporate cerebrospinal fluid levels of total tau (t-tau) and phosphorylated (p-tau) as primary outcomes and how differing biomarker inclusion criteria affect power. We used data from the Alzheimer's Disease Neuroimaging Initiative to model trial scenarios and to estimate the variance and within-subject correlation of total and phosphorylated tau. These estimates were then used to investigate the differences in study power for trials considering these two surrogate outcomes. RESULTS: Patient characteristics were similar for all eligibility criteria. The lowest outcome variance and highest within-subject correlation were obtained when phosphorylated tau was used as an eligibility criterion, compared to amyloid beta or total tau, regardless of whether total tau or phosphorylated tau were used as primary outcomes. Power increased when eligibility criteria were broadened to allow for enrollment of subjects with either low amyloid beta or high phosphorylated tau. CONCLUSION: Specific biomarker inclusion criteria may impact statistical power in trials using total tau or phosphorylated tau as the primary outcome. In concert with other important considerations such as treatment target and population of clinical interest, these results may have implications to the integrity and efficiency of prodromal Alzheimer's disease trial designs.
BACKGROUND/AIMS: The focus of Alzheimer's disease studies has shifted to earlier disease stages, including mild cognitive impairment. Biomarker inclusion criteria are often incorporated into mild cognitive impairment clinical trials to identify individuals with "prodromal Alzheimer's disease" to ensure appropriate drug targets and enrich for participants likely to develop Alzheimer's disease dementia. The use of these eligibility criteria may affect study power. METHODS: We investigated outcome variability and study power in the setting of proof-of-concept prodromal Alzheimer's disease trials that incorporate cerebrospinal fluid levels of total tau (t-tau) and phosphorylated (p-tau) as primary outcomes and how differing biomarker inclusion criteria affect power. We used data from the Alzheimer's Disease Neuroimaging Initiative to model trial scenarios and to estimate the variance and within-subject correlation of total and phosphorylated tau. These estimates were then used to investigate the differences in study power for trials considering these two surrogate outcomes. RESULTS: Patient characteristics were similar for all eligibility criteria. The lowest outcome variance and highest within-subject correlation were obtained when phosphorylated tau was used as an eligibility criterion, compared to amyloid beta or total tau, regardless of whether total tau or phosphorylated tau were used as primary outcomes. Power increased when eligibility criteria were broadened to allow for enrollment of subjects with either low amyloid beta or high phosphorylated tau. CONCLUSION: Specific biomarker inclusion criteria may impact statistical power in trials using total tau or phosphorylated tau as the primary outcome. In concert with other important considerations such as treatment target and population of clinical interest, these results may have implications to the integrity and efficiency of prodromal Alzheimer's disease trial designs.
Authors: Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Kaj Blennow; Henrik Zetterberg; Lennart Minthon; Lars Lannfelt; Stig Strid; Peter Annas; Hans Basun; Niels Andreasen Journal: Neurosci Lett Date: 2007-04-06 Impact factor: 3.046
Authors: Vladimir Coric; Stephen Salloway; Christopher H van Dyck; Bruno Dubois; Niels Andreasen; Mark Brody; Craig Curtis; Hilkka Soininen; Stephen Thein; Thomas Shiovitz; Gary Pilcher; Steven Ferris; Susan Colby; Wendy Kerselaers; Randy Dockens; Holly Soares; Stephen Kaplita; Feng Luo; Chahin Pachai; Luc Bracoud; Mark Mintun; Joshua D Grill; Ken Marek; John Seibyl; Jesse M Cedarbaum; Charles Albright; Howard H Feldman; Robert M Berman Journal: JAMA Neurol Date: 2015-11 Impact factor: 18.302
Authors: Alexandre Bejanin; Daniel R Schonhaut; Renaud La Joie; Joel H Kramer; Suzanne L Baker; Natasha Sosa; Nagehan Ayakta; Averill Cantwell; Mustafa Janabi; Mariella Lauriola; James P O'Neil; Maria L Gorno-Tempini; Zachary A Miller; Howard J Rosen; Bruce L Miller; William J Jagust; Gil D Rabinovici Journal: Brain Date: 2017-12-01 Impact factor: 13.501
Authors: Henrietta Wellington; Ross W Paterson; Erik Portelius; Ulrika Törnqvist; Nadia Magdalinou; Nick C Fox; Kaj Blennow; Jonathan M Schott; Henrik Zetterberg Journal: Neurology Date: 2016-01-29 Impact factor: 9.910
Authors: Matthew R Brier; Brian Gordon; Karl Friedrichsen; John McCarthy; Ari Stern; Jon Christensen; Christopher Owen; Patricia Aldea; Yi Su; Jason Hassenstab; Nigel J Cairns; David M Holtzman; Anne M Fagan; John C Morris; Tammie L S Benzinger; Beau M Ances Journal: Sci Transl Med Date: 2016-05-11 Impact factor: 17.956